![Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business](https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2018/02/931/506/drugs-with-prescription-pad_large-f2815d7acd668510VgnVCM200000d6c1a8c0____-2.jpg?ve=1&tl=1)
Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business
![Why Is Teva Pharmaceuticals Stock Surging After Hours? - Teva Pharmaceutical Indus (NYSE:TEVA) - Benzinga Why Is Teva Pharmaceuticals Stock Surging After Hours? - Teva Pharmaceutical Indus (NYSE:TEVA) - Benzinga](https://cdn.benzinga.com/files/images/story/2022/07/26/stock-market-2616931_1280.jpg?width=1200&height=800&fit=crop)
Why Is Teva Pharmaceuticals Stock Surging After Hours? - Teva Pharmaceutical Indus (NYSE:TEVA) - Benzinga
![Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20190401005452/en/712257/5/Ajovy_UK_Packshot_1pack-HiRes_highres.jpg)
Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire
![Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' | Markets Insider Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' | Markets Insider](https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2022/08/05/screen_shot_2022-08-05_at_11.20.19_am.png)
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' | Markets Insider
![TEVA stock lower as company eyes up to $3.6 billion to settle opioid claims - Reuters | Seeking Alpha TEVA stock lower as company eyes up to $3.6 billion to settle opioid claims - Reuters | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320998287/image_1320998287.jpg?io=getty-c-crop-4-3)